Genome-wide investigation of persistence to treatment with methotrexate in early rheumatoid arthritis
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVES: To investigate the influence of genetic factors on persistence to treatment of early rheumatoid arthritis (RA) with methotrexate (MTX) monotherapy.
METHODS: We conducted a genome-wide association study (GWAS) in a sample of 3902 Swedish early RA patients initiating MTX in DMARD-monotherapy as their first ever DMARD. The outcome, short- and long-term persistence to this treatment, was defined as remaining on MTX at one and at three years, respectively, with no additional DMARDs added. As genetic predictors, we investigated individual SNPs, and a polygenic risk score (PRS) based on SNPs associated with RA risk. The SNP-based heritability of persistence was estimated overall and by RA serostatus.
RESULTS: No individual SNP reached genome-wide significance (p < 5e-8), neither for persistence at one nor at three years. The RA PRS was not significantly associated with persistence at one (RR = 0.98 (0.96-1.01)) nor three years (RR = 0.96 (0.93-1.00)). The heritability for persistence was estimated to be 0.45 (0.15-0.75) at one year and 0.14 (0-0.40) at three years. Results in seropositive RA were comparable to those in the analysis of RA overall, while heritability estimates and PRS RRs were attenuated towards the null in seronegative RA.
CONCLUSIONS: Despite being the largest GWAS on an MTX treatment outcome to date, no genome-wide significant associations were detected. The modest heritability observed, coupled with the broad spread of suggestively associated loci, indicate that genetic influence is of polygenic nature. Nevertheless, persistence to MTX monotherapy was lower in patients with a greater genetic disposition, per the PRS, towards RA.
| Errataetall: |
ErratumIn: Rheumatology (Oxford). 2023 Oct 12;:. - PMID 37830303 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - (2023) vom: 16. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Öberg Sysojev, Anton [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 13.10.2023 published: Print-Electronic ErratumIn: Rheumatology (Oxford). 2023 Oct 12;:. - PMID 37830303 Citation Status Publisher |
|---|
| doi: |
10.1093/rheumatology/kead301 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358284171 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358284171 | ||
| 003 | DE-627 | ||
| 005 | 20231226074419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead301 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358284171 | ||
| 035 | |a (NLM)37326842 | ||
| 035 | |a (PII)kead301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Öberg Sysojev, Anton |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genome-wide investigation of persistence to treatment with methotrexate in early rheumatoid arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Rheumatology (Oxford). 2023 Oct 12;:. - PMID 37830303 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: To investigate the influence of genetic factors on persistence to treatment of early rheumatoid arthritis (RA) with methotrexate (MTX) monotherapy | ||
| 520 | |a METHODS: We conducted a genome-wide association study (GWAS) in a sample of 3902 Swedish early RA patients initiating MTX in DMARD-monotherapy as their first ever DMARD. The outcome, short- and long-term persistence to this treatment, was defined as remaining on MTX at one and at three years, respectively, with no additional DMARDs added. As genetic predictors, we investigated individual SNPs, and a polygenic risk score (PRS) based on SNPs associated with RA risk. The SNP-based heritability of persistence was estimated overall and by RA serostatus | ||
| 520 | |a RESULTS: No individual SNP reached genome-wide significance (p < 5e-8), neither for persistence at one nor at three years. The RA PRS was not significantly associated with persistence at one (RR = 0.98 (0.96-1.01)) nor three years (RR = 0.96 (0.93-1.00)). The heritability for persistence was estimated to be 0.45 (0.15-0.75) at one year and 0.14 (0-0.40) at three years. Results in seropositive RA were comparable to those in the analysis of RA overall, while heritability estimates and PRS RRs were attenuated towards the null in seronegative RA | ||
| 520 | |a CONCLUSIONS: Despite being the largest GWAS on an MTX treatment outcome to date, no genome-wide significant associations were detected. The modest heritability observed, coupled with the broad spread of suggestively associated loci, indicate that genetic influence is of polygenic nature. Nevertheless, persistence to MTX monotherapy was lower in patients with a greater genetic disposition, per the PRS, towards RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a genetic polymorphism | |
| 650 | 4 | |a heritability | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a persistence | |
| 650 | 4 | |a predictors | |
| 650 | 4 | |a rheumatoid arthritis | |
| 700 | 1 | |a Saevarsdottir, Saedis |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Gallo, Lina Marcela |e verfasserin |4 aut | |
| 700 | 1 | |a Silberberg, Gilad N |e verfasserin |4 aut | |
| 700 | 1 | |a Alfredsson, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Klareskog, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Baecklund, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Björkman, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Kastbom, Alf |e verfasserin |4 aut | |
| 700 | 1 | |a Rantapää-Dahlqvist, Solbritt |e verfasserin |4 aut | |
| 700 | 1 | |a Turesson, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Jonsdottir, Ingileif |e verfasserin |4 aut | |
| 700 | 1 | |a Stefansson, Kari |e verfasserin |4 aut | |
| 700 | 1 | |a Frisell, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Padyukov, Leonid |e verfasserin |4 aut | |
| 700 | 1 | |a Askling, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Westerlind, Helga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g (2023) vom: 16. Juni |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead301 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 06 | ||